Kayne Anderson Rudnick Investment Management
VAXX

Kayne Anderson Rudnick Investment Management’s Vaxxinity, Inc. Class A Common Stock VAXX Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio VAXX Stock Details VAXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,089
Closed -$6.03K – 1005
2023
Q4 		$6.03K Buy
+7,089
New +$6.85K ﹤0.01% 646

Other funds holding VAXX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
SAS
Stelac Advisory Services New York $537M AUM 30.43% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's VAXX Position: Q1 2024 in Review

Kayne Anderson Rudnick Investment Management sold out of Vaxxinity, Inc. Class A Common Stock (VAXX) in Q1 2024, closing a stake of 7,089 shares — an estimated $6.03K sold.

Kayne Anderson Rudnick Investment Management first reported a position in VAXX in Q4 2023 and held it in 1 quarter. The position peaked at $6.03K in Q4 2023. 58 funds tracked by Wall St. Rank hold VAXX as of Q1 2024.

  • Kayne Anderson Rudnick Investment Management reported no remaining Vaxxinity, Inc. Class A Common Stock position as of Q1 2024 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 7,089 Vaxxinity, Inc. Class A Common Stock shares in Q1 2024, an estimated $6.03K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Vaxxinity, Inc. Class A Common Stock in Q4 2023 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Vaxxinity, Inc. Class A Common Stock position peaked at $6.03K in Q4 2023.
  • 58 funds tracked by Wall St. Rank held Vaxxinity, Inc. Class A Common Stock as of Q1 2024.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q1 2024, filed 14 May 2024.